Obesity represents a complex metabolic disorder that has significant implications for public health. It is increasingly ...

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without ...

In 2026 patents on semaglutide (the active ingredient in Wegovy and Ozempic) will expire in large emerg­ing markets including ...

While the UK also lacks a law like Italy’s, its National Health Service does classify obesity as a chronic, urgent condition, with emphasis on prevention and long term treatment.

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...

WASHINGTON (AP) — President Donald Trump has pardoned the former Tennessee House speaker and a onetime aide of public ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its ...

Objectives The 2019 Lancet Commission report introduced the concept of a ‘syndemic’, emphasising the complex interplay between malnutrition, obesity and climate change. This updated systematic review ...

Pfizer Inc. is threatening legal action at an attempt by Novo Nordisk A/S to scupper its acquisition of Metsera Inc., with an unsolicited $9 billion offer for the anti-obesity specialist. That trumps ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.